Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
Pirtobrutinib for First-Line CLL/SLL: Pooled Trial Promising Results #CLL | EHA 2026
HealthTreeDescription
Dr. Jennifer Woyach presents pooled results from the BRUIN CLL-313 and BRUIN CLL-314 trials, studying pirtobrutinib (a next-generation BTK inhibitor) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who haven't received prior treatment.
ABOUT PIRTOBRUTINIB:
A newer BTK inhibitor designed to be more selective and potentially overcome resistance seen with earlier BTK inhibitors. Being studied as a first-line treatment option.
WHAT THE TRIALS STUDIED:
Two large clinical trials (BRUIN CLL-313 and BRUIN CLL-314) testing pirtobrutinib in previously untreated CLL/SLL patients. This analysis combines results from both trials for a more complete picture.
WHY THIS MATTERS:
First-line treatment choices are critical in CLL. Having more effective options that work well upfront could improve long-term outcomes and quality of life for patients.
THE FOCUS:
This poster presentation highlights early efficacy and safety data from the combined trial population.
Learn more: https://linktr.ee/HealthTreeUniversity
TIMESTAMPS:
0:00 Introduction & Background
0:54 Pooled Analysis Overview
1:29 Early Data: Results & Safety
#CLL #SLL #Pirtobrutinib #BTKInhibitor #ClinicalTrial